Graham Clarke Email & Phone Number

Gothenburg, Se

Cambridge, Cambridgeshire, Gb

Leading Successful Collaborations and Building Organisations:• Led and closed 4yr fully integrated strategic collaboration agreement with specialistCRO promoting the discovery, development, and diagnostic potential of predictivebiomarkers in fibrotic disease across the Early R&I portfolio• Leading integrated Rare Disease/ Immunology precision medicine operationalstrategies through Alexion/ AZ – linking through CRO Alliance partnering• Led re-structuring preferred provider rate card with key proteomic platform provider todrive 25-35% saving across portfolio• Enabling Precision Medicine: AZ Lead for 3TR-IMI Consortium-– enabling opportunitiesto differentiate established brands (Tezspire) and accelerating mechanistic insights forearly Immunology (RA/SLE) and COPD assets through sample and omic data access• Responsible for the implementing breathomics strategy and road map to integratedomics connecting targets and biomarkers to clinical line of sight• Architect of new functional biomarker operations group to articulate risk to delivery andprovide proactive mitigation steps to influence costs and timelines• Engineered Great Place to Work framework for the group - resulting in a net 18%improvement on key indices such as operational effectiveness and communication overa 6-month period

Cambridge, Cambridgeshire, Gb

London, Greater London, Gb

• Consulted on successful award of investment for new diagnostic unit.• Drug development investment/ decision criteria- triaging a target to market.• Precision Medicine in Immunological Disease / Trial design and execution

London, Gb

• Collaborated in developing an industry leading ex-vivo -human in vitro personalised cytokine storm response assay for early compound development.https://bps.conference-services.net/resources/344/3974/pdf/PHARM15_0204.pdf• Currently lecture on Respiratory drug development, Clinical pharmacology and innovations in human in vitro assay development in adaptive/integrated study designs.

London, Gb

• Responsible for the conduct and co-ordination of research ethics and clinical trials within the department of Cardiothoracic Pharmacology. • Initiated clinical and laboratory services to include pulmonary and bronchial blood flow procedures in patients with pulmonary hypertension and COPD.

London, England, Gb

Change Management and Business Growth• Responsible for delivering the Precision Development Framework – connecting new “Tool Kit” products and predictive algorithms from R&D to the clinic. • Responsible for enabling the delivery $30-40M / year portfolio.• High focus on change and process management creating a flexible and adaptable clinical and trial management team.• Responsible for a 100+ staffed division with Director level line reports.• Responsible for the profitable and efficient management of Viral Challenge quarantine units and UK and US screening centres.

Durham, North Carolina, Us

Strategic and Operational Leadership:• Responsible for developing novel strategies to accelerate clinical development programmes, optimising operational conduct and providing expert subject matter scientific in-put to over 80 first time in man (FTIM) and first time in patient (FTIP) respiratory and allergy indicated studies.• Directly lead clinical and laboratory teams and provided matrix management leadership across several preferred providers mid to large pharma and emerging biotech programmes.• Created a KOL and global partner site network focusing on key indicators such as patient recruitment, scientific and technical expertise with emphasis on data quality and timelines.Thought leadership and Innovation:• Highly experienced in developing generic inhaled devices for bioequivalence studies and integrated study SAD/MAD/POC designs involving challenge test such as Allergen and LPS.• Created a new GP/primary care outreach service to improve COPD, diabetes and GI patient engagement and recruitment. Saw 30%+ increase in COPD screening appointments.• Created the BIOSPIT initiative and global tissue distribution uniting Quintiles ECD, Later phase groups and Global Laboratories to improve sputum data outcomes in multi-centre trials. https://www.ncbi.nlm.nih.gov/pubmed/?term=BIOSPIT

Durham, North Carolina, Us

I lead a highly professional and dedicated multi-disciplinary team, creating two highly successful and fully integrated clinical and biomarker development departments.

Durham, North Carolina, Us

Durham, North Carolina, Us

• Responsible for the operation of the private cardio-pulmonary service and the clinical trials laboratory service for RCT Ltd within this niche boutique CRO.• Created a new central site facility for multiplex analytical platform analysis, whole blood FACS analysis and neutrophil elastase activity assays from airway samples.

London, Greater London, Gb

• Following the submission of my PhD, I was responsible for the performance and monitoring of all physiological measurements to the highest standards in this academic Phase II-IV CRO. I trained nurses, technicians and junior physiologists to perform spirometry, body plethysmography, exhaled nitric oxide and a number of protocol specific respiratory investigations. • Extended my PhD research to assess the impact of inhaled allergen on vascular and airway responses in asthma and healthy volunteers.

London, Greater London, Gb

London, Gb

Teddington, Middlesex, Gb

Working for the national DNA database for the Laboratory of the Government Chemist as a DNA analyst. Duties included DNA extraction, PCR, sequencing and analysis.

London, Gb

Following a successful industrial placement the previous year at the Applied Development Laboratoratories at Bart's Hospital (based as the formerly named ICRT - Imperial Cancer Research Technology), I was employed soon after the end of my degree to cover a maternity placement. Researched the putative tumour supressor gene PTEN

Ph.D, Respiratory Pharmacology And Physiology. -

Bsc, Biomedical Sciences